Compounds, compositions, and methods
AssigneeDenali Therapautics Inc.
InventorsAnthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Claims27
A method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of Parkinson's disease, dementia, Alzheimer's disease, L-Dopa induced dyskinesia, and amyotrophic lateral sclerosis, the method comprising administering to a subject in need thereof an effective amount of a compound of formula Ia:
- or a pharmaceutically acceptable salt, deuterated analog, prodrug, stereoisomer, or a mixture of stereoisomers thereof, wherein:
- R1 is optionally substituted cycloalkyl or C1-6 alkyl optionally substituted with halo;
- R2 is halo, cyano, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted cycloalkyl, optionally substituted C1-6 alkoxy, optionally substituted cycloalkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylsulfonyl, —C(O)R10, or —C(O)N(R11)(R12);
- R3 is optionally substituted C1-6 alkoxy, optionally substituted cycloalkyl, optionally substituted cycloalkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylsulfonyl, or —N(R11)(R12);
- R4 is hydrogen or halo;
- R6 and R7 are each independently hydrogen or C1-6 alkyl optionally substituted with halo;
- R8 and R9 are each independently hydrogen, cyano, halo, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or optionally substituted heteroaryl;
- R10 is optionally substituted C1-6 alkyl or optionally substituted C1-6 alkoxy;
- and
- R11 and R12 are each independently hydrogen, optionally substituted C1-6 alkyl, or optionally substituted cycloalkyl.
A method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of Parkinson's disease, dementia, Alzheimer's disease, L-Dopa induced dyskinesia, and amyotrophic lateral sclerosis, the method comprising administering to a subject in need thereof an effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of Parkinson's disease, dementia, Alzheimer's disease, L-Dopa induced dyskinesia, and amyotrophic lateral sclerosis, the method comprising administering to a subject in need thereof an effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of Parkinson's disease, dementia, Alzheimer's disease, L-Dopa induced dyskinesia, and amyotrophic lateral sclerosis, the method comprising administering to a subject in need thereof an effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of Parkinson's disease, dementia, Alzheimer's disease, L-Dopa induced dyskinesia, and amyotrophic lateral sclerosis, the method comprising administering to a subject in need thereof an effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of Parkinson's disease, dementia, Alzheimer's disease, L-Dopa induced dyskinesia, and amyotrophic lateral sclerosis, the method comprising administering to a subject in need thereof an effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.